Cite

HARVARD Citation

    Ruicci, K. et al. (2019). A controlled trial of HNSCC patient‐derived xenografts reveals broad efficacy of PI3Kα inhibition in controlling tumor growth. International journal of cancer. 145 (8), pp. 2100-2106. [Online]. 
  
Back to record